Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Paris Brain Institute, |
RCV000000012 | SCV001451119 | pathogenic | Hereditary spastic paraplegia 48 | criteria provided, single submitter | clinical testing | ||
Athena Diagnostics | RCV004998069 | SCV005622007 | pathogenic | not provided | 2024-06-25 | criteria provided, single submitter | clinical testing | This variant is expected to result in the loss of a functional protein. This variant has not been reported in large, multi-ethnic general populations. (http://gnomad.broadinstitute.org) This variant has been identified in at least one individual with clinical features associated with this gene. This variant appears to segregate with disease associated with this gene in at least one family. |
Ophthalmic Genetics Group, |
RCV005255549 | SCV005909190 | likely pathogenic | Macular dystrophy with or without extraocular features | 2024-12-17 | criteria provided, single submitter | research | This change likely results in a nonsense-mediated mRNA decay. It is not present in gnomAD v2.1.1 and was previously observed in individuals with complicated spastic paraplegia (reported in ClinVar). It was identified in an affected individual with macular dystrophy, without extraocular features. This variant was classified as Likely pathogenic based on ACMG criteria: PVS1_vstrong, PM2_mod. |
OMIM | RCV000000012 | SCV000020155 | pathogenic | Hereditary spastic paraplegia 48 | 2010-06-29 | no assertion criteria provided | literature only |